The American Society of Nephrology (ASN) this year had a multitude of
interesting sessions on new developments in the understanding and
management of kidney disease. Exemplifying the challenges faced by
companies doing clinical trials during the pandemic, one presentation
focused on the operational issues seen for the large FLOW kidney
outcomes trial in relation to COVID-19. In addition, kidney-related data
from the RESCUE trial with ziltivekimab were shared.